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ABSTRACT
Objective Nephrogenic systemic fibrosis (NSF) is
a generalised fibrotic disorder occurring in certain
individuals with renal insufficiency exposed to gadoliniumbased contrast agents (GdBCA) for MRI. Histopathological
examination of affected tissues shows increased numbers
of activated macrophages. To elucidate the mechanisms
responsible for macrophage activation, the effects of the
GdBCA Omniscan on normal human macrophage global
gene expression, chemokine production and nuclear
factor κB (NFκB) activation was examined.
Methods Normal human monocyte-derived
macrophages were incubated with Omniscan (50 mM)
and their gene expression analysed by microarrays
and real-time PCR. Macrophage chemokine production
was assayed by multiplex ELISA. NFκB activation was
assessed by NFκB nuclear localisation and quantitation
of intracellular levels of inducible nitric oxide synthase
(iNOS) protein. A specific cell-permeable NFκB peptide
inhibitor was used to abrogate NFκB stimulation of
chemokine and iNOS protein levels. CCL8/MCP-2 in
affected skin of patients with NSF was examined by
indirect immunofluorescence.
Results Omniscan caused a profound change in
the transcriptome of differentiated human normal
macrophages in vitro, including a large increase in the
expression of genes encoding CC and CXC chemokines. It
induced rapid nuclear localisation of NFκB and stimulation
of iNOS protein levels and chemokine production which
were blocked by an NFκB inhibitory peptide. CCL8/
MCP-2, the most upregulated chemokine following in
vitro macrophage exposure to Omniscan, was strongly
increased in NSF-affected skin.
Conclusion The GdBCA Omniscan induces potent
stimulation of macrophage gene expression, NFκB
activation and increased NFκB-mediated production of
CC and CXC chemokines and iNOS. These alterations may
play a crucial role in the pathogenesis of NSF.

INTRODUCTION
Nephrogenic systemic ﬁbrosis (NSF), previously
known as nephrogenic ﬁbrosing dermopathy, is a
generalised ﬁbrotic disorder occurring in individuals with renal insufﬁciency following exposure
to gadolinium-based contrast agents (GdBCA)
used to enhance MRI.1–5 Clinically, NSF displays
many similarities to the clinical manifestations of
2024

systemic sclerosis including severe and usually progressive skin induration, progressive and eventually
incapacitating joint ﬂexion contractures and ﬁbrotic
involvement of numerous internal organs including
lungs, heart, diaphragm and striated muscles.1–8
The association of NSF with GdBCA administration has been supported by extensive clinical and
epidemiological studies describing the onset of
NSF in close temporal relationship with GdBCA
use9–14 and the presence of Gd in affected tissues
from patients with NSF.15–18 Furthermore, potent
functional effects of GdBCA have recently been
described on human peripheral blood monocytes,19
human skin organ cultures20 and cultured human
dermal ﬁbroblasts.21,22
Following intravenous administration, GdBCA
distribute rapidly through the intravascular and
extracellular space compartments and Gd chelates are excreted by glomerular ﬁltration, with
>95% excreted by 1 day, a biological elimination
half-life of approximately 1.5 h and no detectable
biotransformation, decomposition or serum protein binding.23,24 Because of the renal excretion of
these compounds and the demonstrated deposition
of Gd in affected tissues of patients with NSF, the
accumulation of Gd in tissues in patients with renal
insufﬁciency is believed to be a crucial event in the
pathogenesis of this condition. Histopathological
studies of tissues from affected individuals with NSF
suggest that, during the early stages of the disease,
the cellular elements involved in the pathogenesis of
NSF are activated macrophages7 and bone marrowderived collagen-producing ﬁbrocytes that inﬁltrate
the affected tissues.25,26 We examined whether
GdBCA could exert a direct effect on human macrophage function and found that Omniscan, the
GdBCA studied, causes a remarkable change in the
transcriptome of normal human macrophages with
a potent stimulation of macrophage chemokine
gene expression and production and activation of
the nuclear factor κB (NFκB) pathway. We further
demonstrated that CCL8/MCP-2 was the most upregulated chemokine in Omniscan-treated macrophages and was also markedly increased in NSF
affected skin. The multifunctional cytokines and
chemokines released from normal macrophages
upon exposure to Omniscan may be able to recruit
circulating mononuclear cells and ﬁbrocytes and
Ann Rheum Dis 2010;69:2024–2033. doi:10.1136/ard.2010.134858
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activate tissue resident ﬁbroblasts to initiate a ﬁbrotic process as
discussed recently.19,22,27 Thus, the data presented here indicate
that the stimulation of chemokine production and activation of
the NFκB pathway in macrophages may play a crucial role in the
pathogenesis of NSF.

MATERIALS AND METHODS
Macrophage isolation and differentiation
Normal human peripheral blood buffy coat preparations
or leuko-reduction ﬁlters were obtained from the Thomas
Jefferson University Hospital Blood Bank following
Institutional Review Board approval. Human peripheral blood
mononuclear cells (PBMCs) were isolated from the buffy coat
or the leukoreduction ﬁlters by Ficoll-Hypaque gradient centrifugation (Amersham Pharmacia Biotech, Piscataway, New
Jersey, USA) and enriched for monocytes by adherence to
plastic culture dishes for 2 h as described.28 To obtain terminally differentiated macrophages the monocytes were cultured
with 60 ng/ml M-CSF (BioVision, Mountain View, California,
USA) and 25 ng/ml interleukin 10 (IL-10) (BioVision) for 7 days
as described.28 Macrophages were activated by incubation in
the same medium for an additional 24 h with 50 nM phorbol myristate acetate (PMA; Acros Organics, Morris Plains,
New Jersey, USA). Activated macrophages (5 × 105 cells/ml)
were exposed for 24 h to 50 mM Omniscan (GE Healthcare,
Lawrence, Massachusetts, USA). No signiﬁcant effects on cell
numbers or increased cytotoxicity were observed as examined by the WST-1 assay (Roche Diagnostics, Indianapolis,
Indiana, USA). Certain experiments were performed with
differentiated macrophages prepared exactly as described
above except that they were not activated by culture with
PMA. Macrophage samples cultured with an equal volume of
phosphate buffered saline (PBS) served as negative controls.
Macrophage culture supernatants were isolated and ﬁltered
and maintained frozen for subsequent studies. Isolation of
total RNA from macrophages was performed as previously
described for human monocytes.19 The Omniscan employed
for all the studies was tested and veriﬁed by the manufacturer
to be free from endotoxin contamination. The endotoxinfree status of Omniscan was further conﬁrmed utilising the
Etoxate Assay (Sigma-Aldrich, St Louis, Missouri, USA) based
on Limulus Ameobocyte Lysate (LAL) gel formation, according to the manufacturer’s instructions.

on an Affymetrix GeneChip Scanner 3000 using GeneChip
Operating Software version 3.0. Raw data were normalised
using Robust Multichip Average and normalised to control
samples with GeneSpring GX v7.3.1 and GX 10.0 software
(Agilent). A volcano plot was used to identify differentially
expressed genes using parametric testing assuming equal
variances and no multiple testing correction. Pathway analysis of differentially expressed genes was performed employing Ingenuity software (Ingenuity Systems, Redwood City,
California, USA).

Real-time PCR validation
Expression levels of CCL2 (MCP-1), CCL8 (MCP-2), CXCL10
(IP10) and CXCL11 (ITAC) were assayed by real-time quantitative PCR using SYBR Green chemistry (Applied Biosystems,
Foster City, California, USA) following a standard ampliﬁcation protocol on an ABI Prism 7900 Sequence Detection
System (Applied Biosystems). The following primers were
employed:
β-Actin: forward 5′-TTGCCGACAGGATGCAGAA-3′, reverse
5′-GCCGATCCACACGGAGTACTT-3′; CCL2 – chemokine, CC
motif, ligand 2: forward 5′-ACCAGCAGCAAGTGTCCCAAA-3′,
reverse5′-TTTGCTTGTCCAGGTGGTCCAT-3′;CCL8–chemokine,
CC motif, ligand 8: forward 5′-TCATGCTGAAGCTCACAC
CCTT-3′, reverse 5′-AGAATTGCCATTGCACAACTCTT-3′;
CXCL10 – chemokine, CXC motif, ligand 10: forward 5′-ACTGCC
ATTCTGATTTGCTGCC-3′, reverse 5′-TGATGCAGGTACAGC
GTACAGT-3′; CXC11 – chemokine, CXC motif, ligand 11:
forward 5′-ACTCCTTCC AAGAAGAGCAGCA-3′, reverse
5′-CCATGCCCTTCACACTCATGTT-3′.
Relative quantiﬁcation was performed by arbitrarily setting
the expression level of the PBS negative control at 100 and by
expressing changes in transcript levels of other samples relative
to this control sample. Relative differences in each PCR sample
were corrected using human β-actin mRNA as an endogenous
control. Some experiments were performed employing terminally differentiated macrophages without prior activation (not
exposed to PMA) to conﬁrm that the observed effects were not
dependent on PMA activation. Other experiments were performed with macrophages incubated with 500 μM caldiamide
to exclude any potential effects that the chelator present in the
Omniscan preparations might have caused on the macrophage
chemokine gene expression.

Analysis of global gene expression patterns

Multiplex ELISA

Global gene expression analysis was performed employing
microarrays. For this purpose macrophages from two different donors prepared and activated as described above were
incubated for 24 h with either PBS or 50 mM Omniscan. Total
RNA was extracted using the RNeasy protocol from Qiagen
(Valencia, California, USA). RNA quality was evaluated using
the Agilent 2100 Bioanalyzer (Agilent, Palo Alto, California,
USA). Total RNA (2 μg) from control and Omniscan-treated
samples (two replicates in each group) were used for
Affymetrix one cycle target labelling as described by the manufacturer (Affymetrix, Santa Clara, California, USA). Each of
four Affymetrix HG U133 plus 2.0 arrays were hybridised for
16 h with biotin-labelled fragmented cRNA (10 μg) in 200 μl
hybridisation mixture according to the manufacturer’s protocol. Arrays were washed and stained using GeneChip Fluidic
Station 450 and hybridisation signals were ampliﬁed using
antibody ampliﬁcation with goat IgG (Sigma-Aldrich) and
anti-streptavidin biotinylated antibody. Chips were scanned

SearchLight proteome array analyses (Pierce Biotechnology,
Woburn, Massachusetts, USA) were conducted to measure the
levels of CCL8, CXCL10, CCL2 and CXCL11 in culture supernatants from terminally differentiated and activated macrophages following incubation with 50 mM Omniscan for 24
h.29 Brieﬂy, culture supernatant samples were diluted 1:2, 1:50 or
1:1000 and then incubated for 1 h on the array plates which had
been prespotted with capture antibodies speciﬁc for each protein. The plates were decanted and washed three times with PBS
before addition of a mixture of biotinylated detection antibodies to each well. Following incubation with detection antibodies
for 30 min, the plates were washed three times and incubated
for 30 min with streptavidin horseradish peroxidase. The plates
were again washed and SuperSignal Femto chemiluminescent
substrate (Pierce Biotechnology) was added. The plates were
immediately imaged using the SearchLight imaging system and
data were analysed using ArrayVision software (GE Healthcare,
Chalfont St Giles, UK).

Ann Rheum Dis 2010;69:2024–2033. doi:10.1136/ard.2010.134858
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Indirect immunofluorescence studies

each incubation with three changes of PBS for 2 min each.
Tissue sections or ﬁxed cells were then counterstained with
4’,6-diamidino-2-phenylindole (DAPI) and analysed using a
Zeiss LSM 510 META Confocal Laser Scanning Microscope
System. Zeiss META confocal microscopy software was used
in balancing signal strength. The breakthrough of the DAPI
signal into the red and green channels was recorded separately
and subtracted from the DAPI blue channel. Each image was
scanned eight times to accurately separate signal from noise.
Panels were assembled using Adobe Photoshop software
without any RGB modiﬁcation. Quantitative analysis of ﬂuorescence was performed using ImageJ software (NIH National
Institute of Mental Health, Bethesda, Maryland, USA). The
integrated density of ﬂuorescence was calculated in three
biopsies and expressed as mean±SD. An unpaired two-tailed t
test was used to calculate p values.

CCL-8 protein was analysed in a sample of normal skin
obtained from a healthy individual and in affected skin
from three different patients with NSF by immunoﬂuorescence using a speciﬁc anti-CCL8 rabbit polyclonal antibody
(ABCAM, Cambridge, Massachusetts, USA). Isotype control
staining was performed using rabbit IgG (Sigma, St Louis,
Missouri, USA). For NFκB localisation studies, macrophages
were exposed to Omniscan or saline for 30 min and then ﬁxed
and permeabilised. Anti-p65-NFκB antibodies (Cell Signaling,
Danvers, Massachusetts, USA) were used at a 1:100 dilution according to the manufacturer’s instructions. Secondary
antibodies were afﬁnity puriﬁed sheep FAB′ anti-rabbit IgG,
Cy3 conjugated (Sigma, St Louis, Missouri, USA). Parafﬁnembedded sections from skin were deparafﬁnated with two
changes of xylene for 10 min each and then two changes of
ethanol for 5 min each. For antigen retrieval the tissue sections
were boiled in 10 mM citrate buffer pH 6.0 for 20 min. The
sections were then rinsed in PBS for 2 min and incubated with
5% (w/v) normal sheep serum for 20 min at room temperature to block non-speciﬁc binding sites. The primary antibody
incubation step was performed in a dark humidiﬁed chamber overnight at 4°C for CCL8. Tissue sections were then
incubated with the sheep polyclonal antibodies (1:200). The
unbound antibodies were removed from the section following

To demonstrate the participation of NFκB activation in the
observed results, macrophages exposed to Omniscan were
pretreated by incubation with a cell-permeable NFκB inhibitory peptide.30 31 The inhibitory peptide was the Iκκ-NBD peptide, which consists of an antennapedia (AP) homeodomain
that confers cell permeability, and the T735 to E745 region
of Iκκβ which is the NEMO binding domain. This peptide
blocks the interaction of NEMO, an IκB complex regulatory
protein, with the IκB complex. The control peptide consists
of the AP homeodomain sequence alone. The Iκκ-NBD and
control peptides (Marligen Biosciences, Ijamsville, Maryland,
USA) were dissolved in dimethyl sulphoxide to a concentration of 6.7 mM. Cells were washed with PBS and exposed
to 200 μM of either Iκκ-NBD or the control peptide for 2 h.
This incubation was followed by addition of either PBS or PBS
with 5, 10, 25 or 50 mM Omniscan for 30 min. Cells were
washed twice in PBS and lysed in 1 ml iNOS buffer. iNOS
protein levels were determined by ELISA as described above.
In other experiments the effects of the cell-permeable NFκB
inhibitory peptide on chemokine expression by macrophages
incubated either in PBS alone or exposed to 50 mM Omniscan
were examined.

Quantitative assessment of iNOS protein levels
Terminally differentiated macrophages were exposed to various
concentrations of Omniscan (5–50 mM) for 90 min and the intracellular levels of inducible nitric oxide synthase (iNOS) protein
were examined in cell lysates of control and Omniscan-treated
cells. The amounts of iNOS present in the macrophage samples
were measured with the Quantising human iNOS ELISA kit
(R&D Systems, Minneapolis, Minnesota, USA) according to the
manufacturer’s protocol. The values of iNOS protein present in
the samples were expressed as U/ml of cellular lysates by comparison with a standard curve prepared employing recombinant
iNOS protein provided by the manufacturer. The calculations
were performed within the linear range of the standard curve
for all samples.

NFκB inhibition studies

Figure 1 (A) Dendrogram showing gene expression differences induced by 50 mM Omniscan in normal human differentiated macrophages. RNA
was isolated from replicate samples of normal human differentiated macrophages incubated under control conditions (C1 and C2) or cultured with
50 mM Omniscan (G1 and G2), labelled and applied to Affymetrix human U133 2.0 Plus microarrays. Dendrograms are reflective of the genes with a
differential expression of more than twofold in the two experimental conditions. In the dendrogram shown, a shorter arm indicates higher similarity
whereas a longer arm indicates lower similarity. (B) Volcano plot of differentially expressed transcripts in the presence of Omniscan. There are four
positive and four negative relative expression values (VG) and log 2 (fold change) shown on the x-axis of the figure. The y-axis is negative base 10
logarithm of the p value for the gene F test (F1). Genes that are significant at the 0.05 multiple test adjusted level are shown in red. Several transcripts
of interest exhibiting twofold or greater increases of expression with p values <0.05 in Omniscan-exposed cells are indicated by arrows.
2026
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RESULTS
Global gene expression of control and Omniscan-exposed
normal human macrophages
Comparison between the average gene expression signals for
the replicates between Omniscan-exposed and control macrophages revealed 551 differentially expressed genes (more than
twofold) (ﬁgure 1A). Table 1 in the online supplement shows a
list of all the differentially expressed genes. In many instances
the differential expression was of a large magnitude (up to
19-fold). A volcano plot analysis of the differentially expressed
transcripts (ﬁgure 1B) revealed that 240 of them were upregulated and 311 were downregulated by more than twofold with
high statistical signiﬁcance (p<0.05). Of these 240 upregulated
transcripts, 31 had a signal intensity >100 and corresponded
to genes with a known function on the NCBI database. We
deﬁned the transcripts for these 31 genes as representing the
‘macrophage Gd signature’. Five of these 31 transcripts corresponded to chemokines and three to interferon-inducible
genes. The complete list is shown in ﬁgure 2. CEL ﬁles for all
the samples analysed will be made publicly available through
the NCBI following publication.

Real-time PCR validation
To validate the microarray results and to further characterise
the chemokine expression levels in macrophages following
incubation with Omniscan, we performed real-time quantitative PCR analysis of mRNA levels for CCL2 (MCP-1), CCL8

(MCP-2), CXCL10 (IP10), CXCL11 (ITAC) and CXCL12 (SDF1)
on the same samples employed for the microarray studies. The
results conﬁrmed and quantiﬁed the microarray results, indicating that expression of these genes was increased in normal
differentiated and activated human macrophages in response
to exposure to 50 mM Omniscan (ﬁgure 3A). Omniscan caused
a potent stimulation of the expression of CCL8 (669±108-fold
increase), CXCL10 (401±72-fold increase), CCL2 (245±36-fold
increase) and CXCL11 (551±48-fold increase) compared with
the PBS control levels. To examine whether previous PMA
activation of macrophages was required for Omniscan stimulation of chemokine expression, four similar experiments were
performed with macrophages without PMA stimulation. The
results in ﬁgure 3B show that PMA activation is not required to
elicit the potent stimulation of chemokine expression in macrophages following exposure to Omniscan, and that the pattern
of chemokine stimulation was qualitatively similar between
samples obtained from Omniscan-exposed macrophages with
or without previous PMA activation. Studies with macrophages
cultured with caldiamide showed that the chelator alone had
no detectable effects on macrophage chemokine gene expression (data not shown). No toxic effects were observed in the
macrophages exposed to 50 mM Omniscan, as indicated by
the absence of cytotoxicity in WST-1 soluble tetrazolium cytotoxicity assays and the observation of similar levels of housekeeping gene transcripts in quantitative PCR arrays (data not
shown).

Figure 2 The macrophage Gd signature genes. Comparisons were performed between transcript expression levels of cells exposed to 50 mM
Omniscan and phosphate buffered saline (PBS) control macrophages on the Affymetrix U133 2.0 Plus microarray, which yielded a group of 31
transcripts excluding orphan genes and transcript redundancies. Genes were considered significant if the p value of the differences was <0.05, the
signal intensity of their expression was >100 and the fold change average signal intensity was >2. Highlighted in red are transcripts for chemokines
of the interferon pathway.

Ann Rheum Dis 2010;69:2024–2033. doi:10.1136/ard.2010.134858
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Figure 3 Effects of Omniscan on the expression and production of chemokines in normal human differentiated macrophages. (A) mRNA expression
levels of four chemokines following treatment of phorbol myristate acetate (PMA)-activated macrophages with 50 mM Omniscan for 24 h. Results
are expressed as mean±SD percentage difference of three replicate samples analysed by quantitative RT-PCR. The phosphate buffered saline
(PBS) control was arbitrarily set to 100% expression. (B) mRNA levels of four chemokines expressed by non-PMA-activated macrophages following
incubation with Omniscan. (C) Levels of secreted chemokines assessed by multiplex ELISA in the supernatants from PMA-activated macrophages
cultured under the same conditions as in (A). The results are expressed as pg/ml of samples analysed in duplicate, each at three different dilution;
***p<0.01.

Multiplex ELISA of tissue culture supernatants from microarray
studies
Culture media isolated from normal human differentiated and
activated macrophages exposed to 50 mM Omniscan were analysed by the Searchlight Proteome Array Assay. Consistent with
the mRNA expression results, we observed a marked increase in
the production and secretion of various chemokines compared
with the levels from control macrophages incubated with PBS.
The concentrations of selected cytokines found in the culture
medium of Omniscan-stimulated macrophages are shown in
ﬁgure 3C.

MCP-2/CCL8 expression is increased in NSF skin
To further validate the in vitro results and to determine
whether the observed increase in chemokine production was
pertinent to the pathogenesis of NSF, we examined the expression of MCP-2/CCL8, the most upregulated chemokine in the
microarray, in parafﬁn-embedded skin biopsies from affected
2028

skin from three patients with NSF. Immunoﬂuorescence studies followed by quantitative confocal microscopy analysis
showed that, in contrast to normal skin from a healthy individual, affected skin from three patients with NSF displayed a
marked increase in the level of ﬂuorescence for MCP-2/CCL8
(ﬁgure 4A); the increase was apparent in both the upper and
lower dermis and was consistent in the three biopsies examined (p<0.0001, ﬁgure 4B).

Pathway analysis of microarray data revealed strong NFκB
activation
Pathway analysis of all the signiﬁcantly (more than twofold,
p<0.05) differentially increased genes in the transcriptome of
Omniscan-treated macrophages indicated a strong activation of
the NFκB pathway (ﬁgure 5). All the macrophage chemokines
found to be upregulated in response to Omniscan exposure are
downstream targets of NFκB activation. Given the strong NFκB
pathway activation suggested by these results, all reagents were
Ann Rheum Dis 2010;69:2024–2033. doi:10.1136/ard.2010.134858
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as early as 5 min after macrophage incubation with 50 mM
Omniscan, a striking NFκB nuclear localisation was observed,
indicating a strong activation of this pathway. The observed
nuclear localisation was completely abrogated by pretreatment
of the macrophages with a cell-permeable NFκB inhibitory (IκκNBD) peptide (ﬁgure 6B) but was not changed by pretreatment
with the AP control peptide.

Omniscan stimulated iNOS protein levels in differentiated
normal human macrophages through NFκB activation
To further conﬁrm the activation of NFκB, we measured the levels
of iNOS protein in cell lysates from differentiated macrophages
without prior PMA activation following incubation with various concentrations (5–50 mM) of Omniscan (ﬁgure 6C,D). The
basal level of iNOS in control macrophages was ~0.015 U/ml of
cell lysate. Following 30 min incubation with all concentrations
of Omniscan there was a potent increase in iNOS levels (10- to
25-fold) with a dose response that reached a plateau at 25 mM
(ﬁgure 6C). To examine the role of NFκB in the stimulation of
iNOS protein levels, the effects of NFκB inhibition by pretreatment with the inhibitory Iκκ-NBD peptide were analysed. The
results are shown in ﬁgure 6D. Exposure to Omniscan caused
a concentration-dependent increase in iNOS protein levels,
with 5 mM inducing a 36-fold increase and 50 mM a 157-fold
increase. This stimulation was essentially completely abolished
by incubation with the Iκκ-NBD inhibitory peptide but was not
affected by the AP control peptide.

Omniscan stimulation of chemokine gene expression is
dependent on NFκB activation

Figure 4 Confocal microscopy imaging of MCP-2/CCL8 expression
in the skin of patients with nephrogenic systemic fibrosis (NSF). (A)
Affected skin samples from three different individuals with NSF were
examined for MCP-2/CCL8 tissue expression with similar results. The
results of one illustrative patient are shown. MCP-2/CCL8 antibodies
(ABCAM) are stained in red. Nuclei are counterstained with DAPI in
blue. Note the intense staining in both the upper and lower dermis of
the NSF biopsy whereas normal skin displays only a dim fluorescence
for MCP-2, mostly around a vessel in the lower dermis. Original
magnification 200×. (B) Quantitative analysis of MCP-2/CCL8 antibody
fluorescence in skin samples from a normal control and from three
patients with NSF. The integrated density of fluorescence (IDF) of the
normal skin (open bar) is compared with the average IDF of the three
NSF skin biopsies (closed bar) and the values are expressed as arbitrary
IDF units (p<0.0001).
conﬁrmed to be endotoxin-free using a LAL gel formation assay
(data not shown).

Omniscan induced NFκB nuclear localisation in terminally
differentiated macrophages
To conﬁrm functionally the NFκB activation suggested by the
pathway analysis, we examined the effects of Omniscan on
NFκB nuclear localisation in normal macrophages. As shown
in ﬁgure 6A, in macrophages incubated under control conditions the localisation of NFκB is mostly cytoplasmic. In contrast,
Ann Rheum Dis 2010;69:2024–2033. doi:10.1136/ard.2010.134858

To determine whether NFκB activation was required for
Omniscan stimulation of macrophage chemokine production,
terminally differentiated macrophages without prior PMA stimulation were preincubated with the NFκB cell-permeable inhibitory peptide and then exposed to Omniscan (50 mM) for 24 h.
Quantitative assessment of transcript levels showed that pretreatment with the Iκκ-NBD peptide completely abrogated the
Omniscan-induced upregulation of CCL8, CXCL10 and CXCL11
and reduced by ~85% the upregulation of CCL2 (ﬁgure 6E).
These results demonstrated that exposure to Omniscan elicits
potent chemokine gene expression stimulation in macrophages
that is dependent on NFκB activation but independent of prior
PMA activation.

DISCUSSION
The activation of tissue macrophages is known to play a critical role during the wound healing process, orchestrating both
the onset and the resolution of the ﬁbrotic phase.32–34 The study
of the pathological processes occurring in systemic ﬁbrotic
diseases such as systemic sclerosis has revealed the presence
of macrophages in the affected tissues, particularly during the
early stages of tissue involvement.35 36 Macrophage inﬁltration
has also been described in the affected skin of patients with
NSF,7 and electron scanning microscopy and energy dispersive
x-ray spectroscopy revealed intracellular Gd deposits in macrophages in affected NSF skin.15 These elegant studies, however,
did not provide any functional evidence that the Gd deposits
caused functional effects or alterations in the macrophage cell
populations.
The studies described here examined directly the role of an
interaction between GdBCA and macrophages by exposing normal differentiated human macrophages to the GdBCA Omniscan.
2029
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Figure 5 Pathway analysis of Omniscan upregulated transcripts. Ingenuity software pathway analysis of the genes most upregulated by Omniscan
indicated that the most represented pathway was the nuclear factor κB (NFκB) signalling pathway. The upregulated genes represented in the
pathway are shown in blue symbols according to Ingenuity classification.
This compound was chosen because it is the most common
GdBCA to which patients who subsequently developed NSF
had been exposed. Another reason for our focus on this GdBCA
was that, in a previous study, we performed a detailed comparison of several GdBCA on PBMC function19 and found that,
despite numerous quantitative and qualitative differences in the
levels of cytokine/chemokine stimulation between the different
GdBCA, the most potent effects were observed with Omniscan.
However, we also performed a microarray analysis on terminally differentiated normal human macrophages incubated with
another GdBCA, Gd-DTPA. The effects of Omniscan were substantially stronger in inducing macrophage activation than those
induced by Gd-DTPA.
The microarray analysis of transcriptome changes occurring in normal human macrophages as a result of exposure to
Omniscan demonstrated a remarkable change in their transcriptome that results in the differential expression of 551 genes, as
depicted in ﬁgure 1 and listed in table 1 in the online supplement. Although the Gd-DTPA data are not described, a table of
the differentially expressed genes in human macrophages following Gd-DTPA stimulation is included in table 2 in the online
supplement. A volcano plot analysis of the most differentially
expressed genes following macrophage exposure to Omniscan
revealed the increased expression of genes encoding numerous
chemokines known to be potent chemoattractants for bone
marrow-derived cells. Although the concentrations of GdBCA
2030

used here are substantially higher than those found in the circulation of individuals with normal renal function following their
administration for imaging studies, the actual concentrations
of these compounds in the tissues of patients with renal insufﬁciency are very likely to be much greater than those calculated from pharmacokinetic studies. For example, in a study of
patients with chronic renal failure on haemodialysis receiving
0.1 mmol/kg administrations of Gd-DTPA (Magnevist) before
haemodialysis, serum concentrations as high as 50 μmol Gd/
ml were observed.37 Furthermore, recent studies have demonstrated the selective accumulation of Gd in macrophages and
ﬁbrocytes in affected skin from patients with NSF,15 suggesting that the distribution of GdBCA in affected tissues is not
homogeneous and that GdBCA can be concentrated in tissue
macrophages resulting in cellular exposure to much higher concentrations of these compounds.
The reasons why only certain individuals with renal insufﬁciency exposed to GdBCA develop NSF are not known.
However, it is very likely that there is great variability in the
cellular response to GdBCA among individuals. Indeed, in
our previous study19 we observed that PBMCs from different
donors display different patterns of activation following incubation with similar concentrations of the same contrast agent. We
have suggested that this variation must be related to a permissive genetic background that may inﬂuence the threshold and
the pattern of cellular activation.
Ann Rheum Dis 2010;69:2024–2033. doi:10.1136/ard.2010.134858
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Figure 6 Cellular localisation of nuclear factor κB (NFκB) in Omniscan-treated differentiated macrophages and Omniscan stimulation of macrophage
inducible nitric oxide synthase (iNOS) protein levels and chemokine production through NFκB activation. (A) Omniscan induction of NFκB nuclear
localisation. Confocal microscopy analysis of terminally differentiated macrophages exposed to 50 mM Omniscan (Gado) for 5 min or maintained
in phosphate buffered saline (PBS). Staining for NFκB p65 was shifted into the nuclei in the Omniscan-treated cells within 5 min of exposure. (B)
Inhibition of nuclear localisation of NFκB p65 by pretreatment with the inhibitory Iκκ-NBD peptide. Panels are representative of three different
experiments on normal human terminally differentiated macrophages (magnification 200×). Antennapedia homeodomain (AP) peptide alone was used
as a control peptide. (C) Dose-dependent stimulation of iNOS protein levels by Omniscan. iNOS protein levels following lipopolysaccharide (LPS) and
Omniscan at concentrations of 5–50 mM were measured. Cells were incubated for 30 min and iNOS protein levels measured in cell lysates using an
ELISA and calculated by comparison with a standard curve obtained with human iNOS recombinant protein. The assays were performed in triplicate.
Values are expressed in U/ml according to the instructions from the manufacturer (R&D Systems). (D) Omniscan induction of iNOS protein levels is
dependent on NFκB activation. iNOS protein levels in terminally differentiated macrophages exposed to either LPS as positive control or Omniscan
in the presence of a control peptide or of the inhibitory Iκκ-NBD peptide. AP peptide alone was used as control. iNOS protein levels were normalised
to the values obtained with macrophages treated with LPS in the absence of any peptide. Values are presented as average and SE of triplicates. (E)
Omniscan stimulation of chemokine expression is dependent on NFκB activation. Chemokine expression in terminally differentiated macrophages
exposed to either LPS as positive control or Omniscan in the presence of a control peptide or of the inhibitory Iκκ-NBD peptide. AP peptide alone was
used as control. Percentage expression of chemokines was normalised on macrophages treated with PBS in the absence of any peptide. The other
values were calculated as multiples thereof. Values are presented as mean and SE of triplicates: ***p<0.01).
The results shown in ﬁgure 3A conﬁrmed and quantiﬁed the
results of the microarray experiments indicating that the expression of numerous chemokine genes was increased in normal
differentiated human macrophages. Furthermore, the results
shown in ﬁgure 3B show that these effects were independent
of PMA macrophage activation. Assessment of chemokine
protein levels in media of GdBCA-exposed macrophages conﬁrmed the increase in production of CCL8, CCL2, CXCL9 and
CXCL11 (ﬁgure 3C). Most importantly, immunoﬂuorescence
studies with confocal microscopy of affected skin from three
patients with NSF indicated that CCL8, the most upregulated
chemokine, was markedly increased in comparison with normal
skin (ﬁgure 4A,B).
To gain an insight into the mechanisms responsible for the
remarkable increase in the macrophage production of these
Ann Rheum Dis 2010;69:2024–2033. doi:10.1136/ard.2010.134858

chemokines in response to Omniscan exposure, we analysed the
cluster of upregulated genes by pathway analysis. This analysis
indicated that most of the chemokines found to be increased
following GdBCA exposure are known to be induced as a result
of the activation of NFκB (ﬁgure 5). To determine whether the
observed macrophage activation was caused by stimulation of
the NFκB pathway we analysed the nuclear localisation of NFκB
and the levels of iNOS in differentiated macrophages following
incubation with Omniscan (ﬁgure 6). We observed that 5 min
incubation was sufﬁcient to induce essentially complete nuclear
localisation of NFκB, indicating a strong activation of this pathway. Furthermore, Omniscan induced a potent dose-dependent
stimulation of iNOS protein levels and chemokine production
in the same cells. Inhibition of intracellular NFκB with a cellpermeable inhibitory peptide showed that NFκB activation was
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necessary for the observed increase in iNOS levels and stimulation of chemokine expression in normal macrophages following
Omniscan exposure.
The data reported here show that GdBCA can induce a potent
activation of normal macrophages and suggest that a similar
mechanism may be responsible for the macrophage activation
observed in NSF-affected tissues. Although these observations
strongly implicate macrophage participation in this unique
ﬁbrotic process, the role of any cell type in NSF is presumptive
since no single cell type has been deﬁnitively demonstrated to
be responsible for the spectrum of histological and pathological changes observed in this condition. Indeed, we consider it
highly unlikely that a single cell type is responsible for mediating all the effects of GdBCA in the induction of NSF. However,
the contention that macrophages may play an important role
in this process is supported by strong experimental evidence
indicating that macrophages play a role in wound healing32–34
and in the pathogenesis of systemic sclerosis.35 36 The involvement of monocytes and macrophages suggested here does not
preclude effects of GdBCA on other cells present in lesions such
as ﬁbrocytes and ﬁbroblasts. Furthermore, it is widely accepted
that there is an increased number of ﬁbrocytes (CD34) in the
skin of patients with NSF. These cells are of bone marrow origin and home to the skin following a speciﬁc chemokine gradient. In this sense, a speciﬁc activation of macrophages causing
increased production and a gradient of chemokines is very likely
to occur and to be crucial in the process.
Although the studies reported here were conducted in vitro,
the kinetics of response we observed, including a potent NFκB
nuclear localisation as early as 5 min following exposure to
Omniscan, suggest that normal human macrophages are capable of reacting directly to the Gd-chelate complex. The kinetics of response and the activation of NFκB are similar to those
observed following lipopolysaccharide stimulation, suggesting
a possible involvement of Toll-like receptor (TLR) signalling in
this process. Additional studies are in progress to further examine the role of TLR signalling in GdBCA-induced macrophage
activation in the initiation and progression of tissue ﬁbrosis.
The results described here show conclusively that Omniscan
is able to activate macrophages and induce their production of
numerous chemokines that are known to be involved in the
pathogenesis of tissue ﬁbrosis. Indeed, we found potent stimulation of chemokines such as CXCL10 which have been shown to
be raised in the serum of some patients with systemic sclerosis38
and to participate in wound healing.39 Furthermore, we clearly
demonstrate that the activation responsible for their production
is NFκB-mediated. Thus, the principal conclusion of the studies
described here is that the GdBCA Omniscan, when in contact
with terminally differentiated macrophages, is able to activate
them towards a proﬁbrotic phenotype and therefore this could
trigger a sequence of events that is responsible for the development of the clinical picture of NSF in a genetically permissive
background. Most importantly, this paradigm could be used to
investigate the very early events in the pathogenesis of idiopathic tissue ﬁbrotic disorders such as systemic sclerosis or idiopathic pulmonary ﬁbrosis, conditions in which the triggering
events are not known, thus precluding a detailed analysis of the
early steps in their pathogenesis. In this regard, environmentallyinduced diseases such as GdBCA-induced NSF may offer a very
valuable model to study the cascade of early events that lead to
a given pathological ﬁbrotic disease phenotype.
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